TAE684 (NVP-TAE684)

For research use only.

Catalog No.S1108

63 publications

TAE684 (NVP-TAE684) Chemical Structure

CAS No. 761439-42-3

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. TAE684 (NVP-TAE684) induces cell cycle arrest and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 2201.25 In stock
RMB 1308.07 In stock
RMB 2379.43 In stock
RMB 6308.29 In stock
RMB 15315.30 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TAE684 (NVP-TAE684) has been cited by 63 publications

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. TAE684 (NVP-TAE684) induces cell cycle arrest and apoptosis.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn4TWM2OD1yLkCwNFA3ODNizszN MkfYV2FPT0WU
SF539 NYTwOJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruXWtJUUN3ME2wMlAxODV4NDFOwG0> M13jPHNCVkeHUh?=
DEL M4HMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3mTWM2OD1yLkCwNFkzPyEQvF2= Mm\5V2FPT0WU
NB1 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH6TWM2OD1yLkCwNVYzKM7:TR?= NV3yb3dyW0GQR1XS
SR NW\vNIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r3eGlEPTB;MD6wNFI4PyEQvF2= M3q1dHNCVkeHUh?=
KARPAS-299 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\IR4J{UUN3ME2wMlAzOzh2IN88US=> MWrTRW5ITVJ?
MHH-CALL-2 NYfDVJl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO5V4JKSzVyPUCuNFI6PTJizszN NXnEWmNKW0GQR1XS
SU-DHL-1 M2DGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnhT2dKSzVyPUCuNFQ5PjVizszN MYfTRW5ITVJ?
A4-Fuk NUT1bpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[0eXlKSzVyPUCuNFU2PjVizszN NE\UfoZUSU6JRWK=
EW-1 NVj2T2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LteWlEPTB;MD6xNFI2PiEQvF2= MYLTRW5ITVJ?
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHzTWM2OD1yLkGwNlk1KM7:TR?= MVXTRW5ITVJ?
EW-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyTWM2OD1yLkGwOVY5KM7:TR?= MW\TRW5ITVJ?
TE-11 NFTDRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHiblZ5UUN3ME2wMlE3ODl4IN88US=> MoLwV2FPT0WU
SW982 NFWxNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjaT3diUUN3ME2wMlE3PDd6IN88US=> NIfJTpNUSU6JRWK=
LAN-6 NXXk[FhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXIWnZbUUN3ME2wMlE4PDR|IN88US=> NV;TNolvW0GQR1XS
MZ1-PC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\0NFdKSzVyPUCuNVc5OzVizszN MmD4V2FPT0WU
KS-1 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LDZmlEPTB;MD6xPVM1OyEQvF2= MXLTRW5ITVJ?
PSN1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HpR2lEPTB;MD6xPVY{OSEQvF2= NIL1WHBUSU6JRWK=
LC-2-ad MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorjTWM2OD1yLkG5OlkzKM7:TR?= NVnZSokxW0GQR1XS
COLO-320-HSR NEDzcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ti[WlEPTB;MD6xPVc4PiEQvF2= NFPVdXFUSU6JRWK=
OPM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHBTWM2OD1yLkKyOlY6KM7:TR?= MkW3V2FPT0WU
SK-NEP-1 NHzqUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\QdWlEPTB;MD6yN|UzPCEQvF2= NYf4O4NYW0GQR1XS
ALL-PO NFnFVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37EfWlEPTB;MD6yOFUzPCEQvF2= MlnDV2FPT0WU
CMK NWO4OpJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaTlBnUUN3ME2wMlI2PTNizszN NH\sc3hUSU6JRWK=
NCI-H1648 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMke4OVUh|ryP M{nHZnNCVkeHUh?=
SIG-M5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33nVWlEPTB;MD6yPVE2QSEQvF2= NUL6bFN4W0GQR1XS
TGBC24TKB NWnhUm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHT45KSzVyPUCuN|AzOThizszN NHzMbWJUSU6JRWK=
DOHH-2 NUn5e|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HlVWlEPTB;MD6zNVIxPCEQvF2= NF3O[|BUSU6JRWK=
NB69 M1nQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\IWZVKSzVyPUCuN|E4QDdizszN MmrpV2FPT0WU
MFH-ino NIK4c2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDsNFJKSzVyPUCuN|I2OjNizszN NXT5R3JIW0GQR1XS
KP-N-RT-BM-1 NYXUNlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfETWM2OD1yLkOzNVI{KM7:TR?= NWP1fVRDW0GQR1XS
MONO-MAC-6 MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjrTWM2OD1yLkOzNlkyKM7:TR?= M3Hz[nNCVkeHUh?=
ATN-1 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHOfXZmUUN3ME2wMlM{OzB|IN88US=> MnXyV2FPT0WU
NTERA-S-cl-D1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPzOnNKSzVyPUCuN|M{QTZizszN M4q4bnNCVkeHUh?=
L-540 NW\oZ5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3GTWM2OD1yLkO2PVg5KM7:TR?= M1;DWXNCVkeHUh?=
GB-1 NVv1W2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwM{i4Olch|ryP MnjZV2FPT0WU
MV-4-11 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjyTWM2OD1yLkO5OFQ3KM7:TR?= MYPTRW5ITVJ?
KG-1 NHvBcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwM{m1OlEh|ryP MWXTRW5ITVJ?
OVCAR-4 NHjKbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7neHBKSzVyPUCuOFA2PjlizszN M17TRXNCVkeHUh?=
NEC8 M4XtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\sTWM2OD1yLkSxNlkzKM7:TR?= NUnT[|hFW0GQR1XS
SK-MM-2 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\STmlEPTB;MD60NVYxQSEQvF2= MonUV2FPT0WU
TE-8 NELqTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjYTWM2OD1yLkSyPFgh|ryP NUPMUoNWW0GQR1XS
697 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD1yLkSzNlE2KM7:TR?= MVTTRW5ITVJ?
NB14 NFHTO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;xdWlEPTB;MD60N|gzPiEQvF2= NWOxVXZQW0GQR1XS
GDM-1 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4NmZKSzVyPUCuOFcyOTZizszN MWHTRW5ITVJ?
HUTU-80 NEn5b|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBfHdKSzVyPUCuOFc{PzVizszN M361SnNCVkeHUh?=
HL-60 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HofWlEPTB;MD60PFE1OiEQvF2= NHjVV2pUSU6JRWK=
OCI-AML2 NXrrSZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rYVWlEPTB;MD60PFMzQCEQvF2= NVjkZZFnW0GQR1XS
ML-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHz[FJKSzVyPUCuOFkxOzFizszN MnTrV2FPT0WU
ES4 NIHmTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HBPWlEPTB;MD60PVExQSEQvF2= MX7TRW5ITVJ?
NCI-H747 NGTBRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLhTWM2OD1yLkS5PFkh|ryP NYrjdWpFW0GQR1XS
RL95-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6TWM2OD1yLkWwNVEzKM7:TR?= NWDPZZliW0GQR1XS
TE-15 M2XXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjGTWM2OD1yLkWxNVI1KM7:TR?= MWnTRW5ITVJ?
TE-12 NEfER3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOzTWM2OD1yLkWzN|Q6KM7:TR?= NVrEO4NyW0GQR1XS
LB1047-RCC NEPhOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDqTWM2OD1yLkW0OVQ6KM7:TR?= Mn;1V2FPT0WU
LB831-BLC NEHneXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxZmlEPTB;MD61OVAzOyEQvF2= NFywbYhUSU6JRWK=
NCI-H1355 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe5ZpBKSzVyPUCuOVUyQDRizszN NVf4UlJYW0GQR1XS
CTV-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXxTWM2OD1yLkW1OlI1KM7:TR?= NXHydodpW0GQR1XS
RXF393 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4b5cyUUN3ME2wMlU2Pzl2IN88US=> Mlz1V2FPT0WU
SW872 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwNU[3NlQh|ryP MUDTRW5ITVJ?
MPP-89 NGXob4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDPTWM2OD1yLkW3PFg1KM7:TR?= MXLTRW5ITVJ?
RPMI-8226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3e3FKSzVyPUCuOlM2OjZizszN NHLpcZJUSU6JRWK=
LS-1034 NYX3T5F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLLU3JKSzVyPUCuOlM2QCEQvF2= NXfpcGFSW0GQR1XS
SJSA-1 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXP[pVuUUN3ME2wMlY{PzJ3IN88US=> NFXS[GZUSU6JRWK=
HOP-62 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:2bWlEPTB;MD62OVA{OyEQvF2= NGnqSIhUSU6JRWK=
KGN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzxe3lKSzVyPUCuOlYyPjhizszN MkjYV2FPT0WU
D-336MG NIrsPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe0VZNKSzVyPUCuOlYyPjlizszN NUPxS2l6W0GQR1XS
LS-411N NV\6S5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNke0OlIh|ryP MU\TRW5ITVJ?
TE-1 NHLHVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\YN3hUUUN3ME2wMlY6ODd2IN88US=> NG\mRXhUSU6JRWK=
LB996-RCC M2WxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwNkmzPFkh|ryP MXfTRW5ITVJ?
TE-10 M13vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHaV4E1UUN3ME2wMlcyPDl4IN88US=> Mn7DV2FPT0WU
NCI-SNU-16 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwN{K2OlQh|ryP MnrQV2FPT0WU
ES8 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwN{S5O|Uh|ryP MYXTRW5ITVJ?
COLO-800 NYXoXGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwN{[2PVUh|ryP MVXTRW5ITVJ?
ES6 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwN{e1OVkh|ryP MVLTRW5ITVJ?
L-363 M4nFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1NWlEPTB;MD64NlM4PSEQvF2= MXXTRW5ITVJ?
NMC-G1 NXi2VXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL4e2VKSzVyPUCuPFMzOzNizszN NH74WHFUSU6JRWK=
LU-134-A M1PUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfvTWM2OD1yLkizPVEzKM7:TR?= M2HOPHNCVkeHUh?=
SF268 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK2TWM2OD1yLki0NFQzKM7:TR?= NXG3ZWxDW0GQR1XS
KARPAS-45 M{jlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3hUphOUUN3ME2wMlg1OjZ|IN88US=> NHTmSG5USU6JRWK=
TGW M3jZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHuTWM2OD1yLki1PFY{KM7:TR?= M1TL[HNCVkeHUh?=
CHP-126 M1rYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nNb2lEPTB;MD64OVk2PyEQvF2= MlXUV2FPT0WU
MOLT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULPNJNWUUN3ME2wMlg4PTh7IN88US=> MnXxV2FPT0WU
LB771-HNC NVLOU3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv5NVRKSzVyPUCuPFk4PTdizszN NWjNTlNqW0GQR1XS
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[0TZJKSzVyPUCuPVA4OzlizszN NITUTlRUSU6JRWK=
GCIY MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17VNmlEPTB;MD65OVUzPiEQvF2= NUm2dWViW0GQR1XS
IST-MES1 NUXFU2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQN25KSzVyPUCuPVg5OjRizszN MXfTRW5ITVJ?
LB2241-RCC M3S2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwOUi4OEDPxE1? MYXTRW5ITVJ?
BL-70 NV:1dG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LGWGlEPTB;MD65PVU{PSEQvF2= NX3hcopDW0GQR1XS
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPsXI5KSzVyPUGuNFA3OzlizszN NFfCVIdUSU6JRWK=
LXF-289 NUfXb45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJeGlEPTB;MT6wN|A4PiEQvF2= NFXBSFdUSU6JRWK=
TK10 M4fXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfycWlrUUN3ME2xMlA2ODZ|IN88US=> MVHTRW5ITVJ?
K5 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\EVmlEPTB;MT6wOlI4PCEQvF2= NXzwVVlsW0GQR1XS
NCI-H716 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jXemlEPTB;MT6wO|I2QSEQvF2= MnvsV2FPT0WU
HCE-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\SXHRuUUN3ME2xMlA5QDF7IN88US=> NFPjW41USU6JRWK=
GI-1 M1PNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLQblFUUUN3ME2xMlA6Pzl6IN88US=> MnjvV2FPT0WU
KARPAS-422 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HZPGlEPTB;MT6xNFAzOiEQvF2= M3PnO3NCVkeHUh?=
TE-9 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HMW2lEPTB;MT6xNVMzQCEQvF2= NXzselE4W0GQR1XS
SF126 NU[4d2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHnTWM2OD1zLkGxOVY5KM7:TR?= M3nteXNCVkeHUh?=
BB30-HNC MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfRcZBKSzVyPUGuNVMyOTJizszN MonVV2FPT0WU
NCI-H1304 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMUOzN|gh|ryP NGLhPXhUSU6JRWK=
HEL NVriOVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZbJo1UUN3ME2xMlE1QDl3IN88US=> M2XsSnNCVkeHUh?=
HAL-01 M1;JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QVXVQUUN3ME2xMlE2Ojh|IN88US=> NEnsTmNUSU6JRWK=
SK-LMS-1 NUPIV2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrKS45KSzVyPUGuNVU6PzRizszN Mn\QV2FPT0WU
SW954 NXfwRmRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHaZ3NpUUN3ME2xMlE6PTZ5IN88US=> MYXTRW5ITVJ?
D-283MED M{Ox[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMkKzO|kh|ryP M2[wNHNCVkeHUh?=
NCI-H1882 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3qTWM2OD1zLkKzPFkh|ryP Mlu0V2FPT0WU
GI-ME-N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXvcFBKSzVyPUGuNlUzODhizszN MlTRV2FPT0WU
SK-PN-DW M3TaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\ETWM2OD1zLkK2N|Q5KM7:TR?= NYDGeW1wW0GQR1XS
C2BBe1 NHHHRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMkmxNVch|ryP MlLlV2FPT0WU
A704 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsTWM2OD1zLkOyOlg6KM7:TR?= NHTBUVNUSU6JRWK=
KALS-1 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwM{SwPEDPxE1? M4DEU3NCVkeHUh?=
ETK-1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK0ZZZCUUN3ME2xMlM1PDh7IN88US=> M4izOHNCVkeHUh?=
LB647-SCLC MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKwTWM2OD1zLkO0PVg3KM7:TR?= MnSxV2FPT0WU
OCUB-M MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHJcYxKSzVyPUGuN|YyPDNizszN MXjTRW5ITVJ?
NCI-H720 M2jzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vjb2lEPTB;MT6zOlM4QCEQvF2= MU\TRW5ITVJ?
NB13 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwM{eyPVMh|ryP MojDV2FPT0WU
GR-ST MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzjbmpKSzVyPUGuN|g4PTdizszN NIDOb2lUSU6JRWK=
DU-4475 NFv4[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIewfXJKSzVyPUGuOFU5PTNizszN NH;6boRUSU6JRWK=
HCC2157 M3ix[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;4PFZKSzVyPUGuOFY3PTlizszN M3rPUHNCVkeHUh?=
RKO NU\QUmFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTCfmVkUUN3ME2xMlQ6QTJ{IN88US=> Ml;4V2FPT0WU
LS-123 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLGVW1KSzVyPUGuOVE2QTRizszN NHjsNYpUSU6JRWK=
NCI-H69 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjjTllKSzVyPUGuOVU5OTFizszN M1fyNnNCVkeHUh?=
SW962 NGfWZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwNU[xN{DPxE1? MX3TRW5ITVJ?
PF-382 NUPzZlJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwNU[5OkDPxE1? MlXVV2FPT0WU
A101D M1\YdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuwW4JzUUN3ME2xMlU4OTF|IN88US=> NWmxOnpGW0GQR1XS
NB10 M4rZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNUezPVIh|ryP Mmr0V2FPT0WU
NB5 NHnab3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPyS4dKSzVyPUGuOVg1PzZizszN MVnTRW5ITVJ?
HCE-4 NFGzV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\OeGdKSzVyPUGuOlA5PSEQvF2= MoXaV2FPT0WU
HT-144 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrlR4hMUUN3ME2xMlY{OTlizszN MULTRW5ITVJ?
NCI-H524 M1;Pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3ISVcxUUN3ME2xMlY1OzB5IN88US=> NFnBXZFUSU6JRWK=
NKM-1 NWfpU5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLwTWM2OD1zLk[4OlYh|ryP MWHTRW5ITVJ?
KURAMOCHI NYPSZZB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;6TWM2OD1zLk[5OVc{KM7:TR?= MnHGV2FPT0WU
NCI-H187 NYDpOWlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTWWY5uUUN3ME2xMlcxODN4IN88US=> NGm4UYhUSU6JRWK=
U-266 M2fZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwN{O4OFIh|ryP NWnLXHBOW0GQR1XS
BL-41 M1L1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyR2lEPTB;MT63OlI4OiEQvF2= MXHTRW5ITVJ?
SK-N-DZ M1;4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwN{izNFkh|ryP NXPHc446W0GQR1XS
Daudi NYDQTXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;ETWM2OD1zLke4PVY4KM7:TR?= M1L5enNCVkeHUh?=
CPC-N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPFc2hKSzVyPUGuPFUxQTZizszN MVLTRW5ITVJ?
EM-2 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT5TWM2OD1zLki1NUDPxE1? NWP0dFN{W0GQR1XS
HCC1187 NE\2O|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzTWM2OD1zLki2NlQyKM7:TR?= MYTTRW5ITVJ?
LP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fJUmlEPTB;MT64O|E1OyEQvF2= NWDmU3Z2W0GQR1XS
CAS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2WoU5UUN3ME2xMlk5Ojl7IN88US=> M16z[XNCVkeHUh?=
NB7 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwMEC1OVUh|ryP M4nyXXNCVkeHUh?=
VA-ES-BJ M{X5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWzfXhvUUN3ME2yMlAyPTF|IN88US=> MmXyV2FPT0WU
SNU-C2B NVnmWY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjWU|Q5UUN3ME2yMlA{OzVzIN88US=> NVTUTm5RW0GQR1XS
LOXIMVI MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD1{LkC2O|g3KM7:TR?= M4L2fHNCVkeHUh?=
NCI-H1581 NH\QcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXOeYxKSzVyPUKuNVE2PTlizszN M4HhOHNCVkeHUh?=
IST-SL2 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJbWlEPTB;Mj6xNlQ1PSEQvF2= MkLXV2FPT0WU
NOMO-1 M2TMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwMUe2PFMh|ryP MmrvV2FPT0WU
TE-6 M3HySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXNTWM2OD1{LkG5NFUh|ryP MVXTRW5ITVJ?
NCI-H526 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwMUmxOFEh|ryP M17F[nNCVkeHUh?=
MSTO-211H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXrPJFKUUN3ME2yMlIxODRzIN88US=> NWjKXZNSW0GQR1XS
LS-513 NX[1dmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1{LkKyNlY6KM7:TR?= Mlz4V2FPT0WU
NCI-SNU-1 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XGV2lEPTB;Mj6zN|I2PiEQvF2= M4PtOHNCVkeHUh?=
BB65-RCC NXzFUYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwM{e0PVMh|ryP M4DsfHNCVkeHUh?=
GT3TKB MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjXPWlIUUN3ME2yMlM6QTd{IN88US=> MXfTRW5ITVJ?
OS-RC-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwNEKzOFEh|ryP NYrQeGlCW0GQR1XS
NCI-H2126 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnyUXdNUUN3ME2yMlQ{Pjd2IN88US=> NWW1[3Z4W0GQR1XS
SK-UT-1 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3NTWM2OD1{LkS3OFY4KM7:TR?= MWDTRW5ITVJ?
DMS-114 M{jHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknDTWM2OD1{Lk[xOVI1KM7:TR?= M4Llb3NCVkeHUh?=
ONS-76 NH;JOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljQTWM2OD1{Lk[zOlQyKM7:TR?= MWHTRW5ITVJ?
8-MG-BA M1faOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\MPGlEPTB;Mj62OVQyPCEQvF2= NV\4cHp4W0GQR1XS
BOKU NHvPZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDQVVBKSzVyPUKuO|I4PjRizszN MWHTRW5ITVJ?
LAMA-84 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnOUWNvUUN3ME2yMlc6QTF{IN88US=> NGHCOZNUSU6JRWK=
ES1 NYqzc|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfreWg{UUN3ME2yMlgyQDB2IN88US=> M{j3bHNCVkeHUh?=
NCI-H1395 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv1NWRKSzVyPUKuPFIxOTJizszN Mn3CV2FPT0WU
A388 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwOU[xO{DPxE1? NXX2ToVOW0GQR1XS
NCCIT MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwMEi4OlIh|ryP MnfwV2FPT0WU
HD-MY-Z NXG2dIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXQTWM2OD1|LkGzNlA{KM7:TR?= NF63NY9USU6JRWK=
NCI-H510A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G4UmlEPTB;Mz6xPFk1OyEQvF2= NEnFUpdUSU6JRWK=
NCI-N87 NYLUc|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwMkCwNkDPxE1? NEHuNXBUSU6JRWK=
SCLC-21H NXjnV|JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XnZ2lEPTB;Mz6yOlg2QSEQvF2= MkPwV2FPT0WU
SH-4 NV21c3BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2[3JWUUN3ME2zMlI5Pzl5IN88US=> MVjTRW5ITVJ?
QIMR-WIL M3HrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwM{K4OFkh|ryP MULTRW5ITVJ?
KM12 M13ZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwM{O1OFQh|ryP M3K0TnNCVkeHUh?=
ST486 M4nuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTjeZBbUUN3ME2zMlU{QDh|IN88US=> M1fzV3NCVkeHUh?=
HC-1 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf2S4w5UUN3ME2zMlYzODJ6IN88US=> MmDmV2FPT0WU
BV-173 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNwNkSwPFgh|ryP M3W1XHNCVkeHUh?=
EW-24 NF\y[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnPT41KSzVyPUOuOlY1OzRizszN MkPyV2FPT0WU
LU-65 M{TOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXkTWM2OD1|Lk[4O|Eh|ryP MoflV2FPT0WU
ECC4 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsWGlEPTB;Mz63O|U3KM7:TR?= NU\oTVlZW0GQR1XS
ARH-77 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwMUGwOlch|ryP NHi5PItUSU6JRWK=
BC-3 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrvOZpKSzVyPUSuNVMxPjhizszN NEDxT4FUSU6JRWK=
SNB75 M4HCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwMk[xPUDPxE1? NYK2bZF[W0GQR1XS
MEG-01 M2XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHPGlEPTB;ND6yO|QyQSEQvF2= MmPQV2FPT0WU
NCI-H1417 M3vK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTRwMki0OFMh|ryP MkfSV2FPT0WU
MDA-MB-134-VI NEC5PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD12LkOwOlAyKM7:TR?= M330PXNCVkeHUh?=
Becker NVXoeVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfZV3RHUUN3ME20MlQ4OzN4IN88US=> M4H1eHNCVkeHUh?=
DMS-153 NE\oR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\yUXpoUUN3ME20MlY3PDd3IN88US=> MWTTRW5ITVJ?
TGBC1TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwNki1NVUh|ryP MWrTRW5ITVJ?
EW-3 NVnqbnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC2UXNKSzVyPUSuO|YzPDhizszN MkKzV2FPT0WU
KE-37 M{G3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLoVZpJUUN3ME20Mlg3OTl4IN88US=> M1iwXXNCVkeHUh?=
NCI-H23 NHflVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwOEeyNlch|ryP Mkm0V2FPT0WU
MC116 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwOUSxNlYh|ryP MXXTRW5ITVJ?
NH-12 M1ewWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK0TWM2OD12Lkm2OFM6KM7:TR?= NUe1VZZLW0GQR1XS
CTB-1 M{DzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRwOUe3NlEh|ryP NVLORXdYW0GQR1XS
KM-H2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HVTmlEPTB;NT6wOVMzOyEQvF2= MnK1V2FPT0WU
MOLT-4 NH3oXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrBXo1KSzVyPUWuNVE5OyEQvF2= Ml;iV2FPT0WU
NCI-H2141 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr4TWM2OD13LkG0NlY5KM7:TR?= NXr6[2pWW0GQR1XS
EB-3 M2PLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTVwMUe1NFQh|ryP MkLnV2FPT0WU
NCI-H1522 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL3[ZBKSzVyPUWuNlY{OjJizszN NUfEVpNwW0GQR1XS
MRK-nu-1 M{WwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\EdmtNUUN3ME21MlQ{PjN|IN88US=> NYrvWXI4W0GQR1XS
no-11 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXNfYZ[UUN3ME21MlQ4ODh5IN88US=> MkHRV2FPT0WU
CESS NF;LbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwNUiwN|Qh|ryP MYnTRW5ITVJ?
KMOE-2 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTVwNUi2OVkh|ryP MXvTRW5ITVJ?
REH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rlR2lEPTB;Nj6yOVYyQCEQvF2= NG\hU3ZUSU6JRWK=
KU812 NVPBVHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT1N4xWUUN3ME22MlQzPzlzIN88US=> NGiyVZdUSU6JRWK=
SK-N-FI M4XxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TkUWlEPTB;Nj62NFY4PCEQvF2= NIjUcXZUSU6JRWK=
MMAC-SF M3fjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHoTWM2OD15LkC2OFkzKM7:TR?= Ml\pV2FPT0WU
RCC10RGB M{nTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HHZWlEPTB;Nz6yNlk4PyEQvF2= NXroPZo5W0GQR1XS
NCI-H322M NEi3V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPiPYtTUUN3ME23MlM{OzN3IN88US=> MX3TRW5ITVJ?
NB6 NF3YU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWwTFA2UUN3ME23MlU1QDl7IN88US=> NILWOI9USU6JRWK=
MN-60 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX2SIFKSzVyPUeuOlkzOTVizszN M1XscnNCVkeHUh?=
NCI-H1092 M37kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGVWlEPTB;OD6wNVc{PCEQvF2= MlTnV2FPT0WU
EKVX MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zWpdnUUN3ME24MlQ4ODZ4IN88US=> MVzTRW5ITVJ?
D-263MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRThwNUWzPVYh|ryP M3[zenNCVkeHUh?=
NCI-H209 NWDlVGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\jTWM2OD16Lk[0NFA3KM7:TR?= M4nCNHNCVkeHUh?=
IST-SL1 NUHqbVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwOEm4PVIh|ryP MnTzV2FPT0WU
ACN NI\3VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0VmlEPTB;OT6xPVE2PyEQvF2= NEnRNZRUSU6JRWK=
MHH-PREB-1 NWH5bWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jSNmlEPTB;OT6yNVIyQSEQvF2= M17JNXNCVkeHUh?=
EW-11 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHIO4JxUUN3ME25MlY2Ozl4IN88US=> MUTTRW5ITVJ?
KASUMI-1 NX;2eZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDVTWM2OD17Lke4O|ch|ryP MYDTRW5ITVJ?
KINGS-1 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT0TWM2OD1zMD6yN|Q4KM7:TR?= M3nVNHNCVkeHUh?=
EVSA-T NGLpeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXUdIhlUUN3ME2xNE4{OTl{IN88US=> MnfoV2FPT0WU
DSH1 M{HxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4OGlEPTB;MUCuN|k4OiEQvF2= M4LNTnNCVkeHUh?=
COLO-824 M3PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXnTWM2OD1zMD64OlY6KM7:TR?= NVnRTGI2W0GQR1XS
K052 NIjDNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPkepBKSzVyPUGwMlk{OjJizszN NYHyRXI4W0GQR1XS
SK-MEL-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG1O5pzUUN3ME2xNE46QTN7IN88US=> NXm2c2p[W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ALK / ALK / p-STAT3 / STAT3 / p-ERK / ERK / p-AKT / AKT / Survivin / BIM / PARP ; 

PubMed: 22240786     


H3122 or H2228 cells were incubated with the indicated concentrations of TAE684 for 48 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms of ALK, STAT3, ERK, or AKT as well as with those to BIM, to survivin, to PARP, or to β-actin (loading control). The positions of the bands for EML4–ALK, BIMEL, and intact and cleaved forms of PARP are shown for the corresponding antibodies. 

p-ROS1 / ROS1 ; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various identified ROS1 inhibitors selected from the high throughput screening. CD74-ROS1-WT-expressing (clone 6) or CD74-ROS1-G2032R-expressing Ba/F3 cells were exposed to increasing concentrations of cabozantinib (XL184), TAE684, or foretinib (B) for 2 h. Following treatment, the cell lysates were immunoblotted to detect the indicated proteins.

22240786 25351743
Growth inhibition assay
Cell viability; 

PubMed: 18594010     


NSCLC cells were treated with TAE-684 at the indicated concentrations, and viable cells were measured after 72 hours of treatment. The percentage of viable cells is shown relative to untreated controls. A549 (KRAS G12S); PC9 (EGFRdelE746_A750); H2228 (EML4-ALK variant 3); H3122 (EML4-ALK variant 1); DFCI032 (EML4-ALK variant 1). 

18594010
In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
- Collapse
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID